| Quantity: | |
|---|---|
Broad model portfolio – Hapten, cytokine, allergen, and vitamin D analog models covering acute, chronic, and Th2/Th17/Th22‑dominant AD endotypes.
Multiple species/strains – BALB/c (Th2‑prone), C57BL/6 (Th1/Th17‑prone), and SD rat available.
Comprehensive endpoints – Body weight, ear thickness, skin score, itch events, serum IgE, cytokine profiling (IL‑4, IL‑13, IL‑17, IL‑36), histopathology (HE, Toluidine Blue), epidermal thickness.
Translational value – Ideal for testing JAK inhibitors, biologics (anti‑IL‑4Rα, anti‑IL‑13), PDE4 inhibitors, and topical agents.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
DNCB Induced C57BL/6 AD Model
DNCB Induced AD Model in BALB/c Mice
OXA Induced C57BL/6 AD Model
OXA Induced BALB/c AD Model
MC903 Induced C57BL/6 AD Model
MC903 Induced BALB/c AD Model
MC903&OXA induced AD model in BALB/c
FITC Induced BALB/c AD Model
DNFB+OVA Induced BALB/c AD Model
IL-33 Induced BALB/c AD Model
IL-36 Induced AD Model in C57BL/6 Mice
HDM+SEB Induced AD Model in C57BL/6 Mice
• Efficacy testing of topical and systemic AD therapies (JAK inhibitors, PDE4 inhibitors, biologics targeting IL‑4/13, IL‑31, IL‑33, TSLP)
• Target validation for Th2, Th17, Th22, and itch pathways
• Biomarker discovery (IgE, cytokine signatures, skin barrier proteins)
• Mechanism of action (MOA) studies
• IND‑enabling pharmacology and toxicology studies
Parameter | Specificatio |
Species/Strain | Mouse (BALB/c, C57BL/6); Rat (SD) |
Induction method | Haptens (DNCB, OXA, DNFB+OVA, FITC), vitamin D analog (MC903), cytokines (IL‑33, IL‑36), allergens (HDM+SEB), combinations (MC903+OXA) |
Study duration | 7–28 days (depending on model) |
Key endpoints | Body weight, ear thickness, skin clinical score, itch events (scratching), serum total IgE & antigen‑specific IgE, cytokine levels (IL‑4, IL‑13, IL‑17, IL‑36, TNF‑α), histopathology (H&E, Toluidine Blue), epidermal thickness, immune cell infiltration (FACS/IHC) |
Data package | Raw data, analysis reports, clinical photographs, histology slides, flow cytometry files, bioinformatics (optional) |
Q: How do I choose the right AD model for my drug candidate?
A: Consider your drug’s mechanism: Th2‑targeted biologics (e.g., anti‑IL‑4Rα) are best evaluated in hapten or MC903 models; Th17‑related compounds may be suited for IL‑36 or HDM+SEB models. BALB/c mice exhibit stronger Th2 responses, while C57BL/6 show more balanced Th1/Th17 profiles. Our scientific team can guide model selection based on your specific target.
Q: Can these models be used for IND‑enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different dosing schedules, combination therapies)?
A: Absolutely. Our scientific team tailors induction protocols, treatment schedules, and endpoint analyses to your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: Most AD models complete within 2–4 weeks, including sensitization/challenge and treatment phases. Specific timelines depend on model choice and endpoints.
